SecBot SecBot
8-K ·Filed May 27, 2026

APGE

Apogee Therapeutics, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed5mo ago SEC0001104659-26-066572
8-K context-dependent: Items 7.01, 8.01
Actionable Insight ▲ Bullish

This is a major derisking catalyst for APGE. The Phase 2 Part B data confirms zumilokibart's best-in-class potential with robust efficacy and transformative dosing (2-4 dosing days/year vs 26 for DUPIXENT). The Blackstone financing removes equity dilution overhang. Key catalysts ahead: Phase 3 initiation 2H 2026, 52-week Part B data 1H 2027, Phase 3 readouts 2028. Monitor for regulatory feedback on Phase 3 dose and any competitive updates from Sanofi's amlitelimab.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$77.75
T+0 close · May 27, 2026 · via day close
Latest settled
+73.31%
T+60 · $134.75
Vs SPY
+71.43%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 27 $77.75entry
  2. T+1 · 6mo ago +0.09%α −0.46% · $77.82
  3. T+5 · 6mo ago +1.23%α +0.03% · $78.71
  4. T+20 · 5mo ago +70.65%α +72.55% · $132.68
  5. T+60 · 3mo ago +73.31%α +71.43% · $134.75
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Apogee Therapeutics announced positive 16-week induction dose optimization results from Part B of the Phase 2 APEX trial of zumilokibart in moderate-to-severe atopic dermatitis. The mid-dose met all primary and secondary endpoints with high statistical significance (EASI-75 65.9% vs 23.4% placebo, p<0.001), supporting planned Phase 3 initiation in 2H 2026. The company also disclosed a strategic financing collaboration with Blackstone Life Sciences expected to provide funding through commercialization without need for future equity financing.

Key Facts

  • APEX Part B met primary endpoint: mid-dose EASI-75 65.9% vs placebo 23.4% (p<0.001)
  • Mid-dose secondary endpoints all met: IGA 0/1 46.0% (p<0.001), EASI-90 47.4% (p<0.001), I-NRS4 50.5% (p<0.001), EASI-100 16.5% (p<0.01), vLDA 20.6% (p<0.01)
  • Mid-dose selected as planned Phase 3 dose; Phase 3 ADventure program (3 trials) expected to initiate 2H 2026
  • Blackstone collaboration provides up to $1.3B in funding including $400M pre-approval and up to $400M approval tranche; max royalty rate 6.25% on up to $5B of WW annual sales
  • Zumilokibart well-tolerated; pooled conjunctivitis rate 10.6% for mid-dose
  • Phase 2b ASPIRE asthma trial expected 1H 2027; Phase 2a ELEVATE EoE trial expected 2H 2026
  • Launch anticipated in 2029

Financial Impact

Blackstone financing provides up to $1.3B; Apogee had $1.3B cash as of March 31, 2026; total capital expected to fund through commercialization without equity financing

cash runwaydilution riskroyalty obligation

Risk Factors

  • Phase 3 trials may fail to replicate Phase 2 results
  • Competitive landscape evolving (amlitelimab, other IL-13/IL-4 agents)
  • Conjunctivitis rate (10.6%) may be scrutinized by regulators
  • Blackstone royalty obligation (up to 6.25% on first $5B sales) reduces peak margin
  • Regulatory interactions could delay Phase 3 initiation timeline

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
83% bullish (23 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-066572
Document: tm2615568d1_8k.htm0001104659-26-066572
Document: tm2615568d1_ex99-1.htm0001104659-26-066572
Document: 0001104659-26-066572-index-headers.html0001104659-26-066572
Document: 0001104659-26-066572-index.html0001104659-26-066572
Document: 0001104659-26-066572.txt0001104659-26-066572

Track record

31 reports on APGE

Performance horizon

8 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +73.31% at T+60 after the May 27, 2026 report. 11 of 12 went positive at some point.

Filters
  1. Sep 14, 20269w ago 15-12G Neutral 4/10 No price data
  2. Sep 3, 202610w ago 25-NSE Bullish 8/10 Entry $135.06 No price data
  3. Sep 3, 202610w ago 8-K Bullish 8/10 Entry $135.06 No price data
  4. Aug 11, 202613w ago 8-K Bullish 7/10 Entry $134.55 No price data
  5. Aug 10, 202614w ago 8-K Bullish 8/10 No price data
  6. Aug 10, 202614w ago Press Release Bullish 8/10 Entry $134.65 No price data
  7. Aug 6, 202614w ago Institutional Cluster Mixed 5/10 Entry $134.49 to $135.07 ▲ +0.43% −0.17% vs SPY
  8. Aug 3, 202615w ago DEFA14A Bullish 5/10 Entry $134.19 to $135.08 ▲ +0.66% +1.90% vs SPY
  9. Jul 10, 202618w ago Insider Cluster Neutral 2/10 Entry $133.82 to $134.65 ▲ +0.62% −2.56% vs SPY
  10. Jun 26, 202620w ago DEFA14A Bullish 6/10 Entry $132.61 to $134.28 ▲ +1.26% +1.54% vs SPY
Showing 10 of 31

US Market Status

Market Closed · Opens in 9h 11m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 27, 2026